



Product Information

Product ID V2792

CAS No. 6501-72-0

Chemical Name

Synonym GIT27

Formula C₁₁H₁₁NO₃

Formula Wt. 205.21

Melting Point


Purity ≥98%

Solubility DMSO: ≥ 56 mg/mL

Store Temp -20°C

Ship Temp Ambient

Description VGX-1027 displays immunomodulatory and anti-inflammatory activities by inhibiting toll-like receptor 4 (TLR4) signaling. In diabetic mice, VGX-1027 decreases synthesis of pro-inflammatory cytokines and improves glomerulosclerosis. In other animal models, this compound inhibits antigen presentation, preventing the development of systemic lupus erythematosus (SLE), increases survival rates and improving overall pathology.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
V2792	5 mg	\$75.80
V2792	10 mg	\$129.20
V2792	50 mg	\$505.70

References Fagone P, Muthumani K, Mangano K, et al. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. *Immunology*. 2014 Aug;142(4):594-602. PMID: 24527796.

Cha JJ, Hyun YY, Lee MH, et al. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. *Endocrinology*. 2013 Jun;154(6):2144-55. PMID: 23568555.

Stojanovic I, Cuzzocrea S, Mangano K, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. *Clin Immunol*. 2007 Jun;123(3):311-23. PMID: 17449326.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.